KWMG
ALXN

King Wealth Management Group’s Alexion Pharmaceuticals ALXN Stock Holding History

King Wealth Management Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,950
Closed -$443K – 166
2020
Q2 		$443K Buy
+3,950
New +$419K 0.13% 89
2019
Q4 		– Sell
-2,750
Closed -$269K – 150
2019
Q3 		$269K Sell
2,750
-500
-15% -$56.4K 0.08% 111
2019
Q2 		$426K Buy
3,250
+1,200
+59% +$155K 0.13% 75
2019
Q1 		$277K Buy
+2,050
New +$255K 0.09% 105

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

King Wealth Management Group's ALXN Position: Q3 2020 in Review

King Wealth Management Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 3,950 shares — an estimated $443K sold.

King Wealth Management Group first reported a position in ALXN in Q1 2019 and held it in 4 quarters. The position peaked at $443K in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • King Wealth Management Group reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • King Wealth Management Group sold 3,950 Alexion Pharmaceuticals shares in Q3 2020, an estimated $443K.
  • King Wealth Management Group first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • King Wealth Management Group's Alexion Pharmaceuticals position peaked at $443K in Q2 2020.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on King Wealth Management Group's 13F filing for Q3 2020, filed 12 Nov 2020.